Essential hypertension

被引:584
作者
Messerli, Franz H.
Williams, Bryan
Ritz, Eberhard
机构
[1] Columbia Univ, Coll Phys & Surg, St Lukes Roosevelt Hosp Ctr, Div Cardiol, New York, NY 10019 USA
[2] Univ Leicester, Sch Med, Leicester, Leics, England
[3] Heidelberg Univ, Heidelberg, Germany
关键词
D O I
10.1016/S0140-6736(07)61299-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Essential hypertension can be defined as a rise in blood pressure of unknown cause that increases risk for cerebral, cardiac, and renal events. In industrialised countries, the risk of becoming hypertensive (blood pressure >140/90 mm Hg) during a lifetime exceeds 90%. Essential hypertension usually clusters with other cardiovascular risk factors such as ageing, being overweight, insulin resistance, diabetes, and hyperlipidaemia. Subtle target-organ damage such as left-ventricular hypertrophy, microalbuminuria, and cognitive dysfunction takes place early in the course of hypertensive cardiovascular disease, although catastrophic events such as stroke, heart attack, renal failure, and dementia usually happen after long periods of uncontrolled hypertension only. All antihypertensive drugs lower blood pressure (by definition) and this decline is the best determinant of cardiovascular risk reduction. However, differences between drugs exist with respect to reduction of target-organ disease and prevention of major cardiovascular events. Most hypertensive patients need two or more drugs for blood-pressure control and concomitant statin treatment for risk factor reduction. Despite the availability of effective and safe antibypertensive drugs, hypertension and its concomitant risk factors remain uncontrolled in most patients.
引用
收藏
页码:591 / 603
页数:13
相关论文
共 147 条
[1]   Prevention of new-onset atrial fibrillation and its predictors with angiotensin II-receptor blockers in the treatment of hypertension and heart failure [J].
Aksnes, Tonje A. ;
Flaa, Arnljot ;
Strand, Arne ;
Kjeldsen, Sverre E. .
JOURNAL OF HYPERTENSION, 2007, 25 (01) :15-23
[2]  
*ALLHAT OFF COORD, 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI DOI 10.1001/JAMA.288.23.2981
[3]   Calcium channel blockade to prevent stroke in hypertension - A meta-analysis of 13 studies with 103,793 subjects [J].
Angeli, F ;
Verdecchia, P ;
Reboldi, GP ;
Gattobigio, R ;
Bentivoglio, M ;
Staessen, AA ;
Porcellati, C .
AMERICAN JOURNAL OF HYPERTENSION, 2004, 17 (09) :817-822
[4]   EFFECTS OF TREATMENT ON MORBIDITY IN HYPERTENSION - RESULTS IN PATIENTS WITH DIASTOLIC BLOOD PRESSURES AVERAGING 115 THROUGH 129 MM HG [J].
不详 .
JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1967, 202 (11) :1028-&
[5]  
[Anonymous], 1905, B IMPERIAL MIL MED A, DOI DOI 10.1097/00004872-200501000-00001
[6]  
[Anonymous], 1970, JAMA-J AM MED ASSOC, V213, P1143, DOI DOI 10.1001/JAMA.213.7.1143
[7]   Fixed-dose combinations improve medication compliance: A meta-analysis [J].
Bangalore, Sripal ;
Kamalakkannan, Gayathri ;
Parkar, Sanobar ;
Messerli, Franz H. .
AMERICAN JOURNAL OF MEDICINE, 2007, 120 (08) :713-719
[8]   Is echocardiography essential in the management of newly diagnosed hypertension? [J].
Bella, Jonathan N. ;
Devereux, Richard B. .
AMERICAN JOURNAL OF HYPERTENSION, 2006, 19 (11) :1156-1157
[9]   Secondary endothelial dysfunction: Hypertension and heart failure [J].
Boulanger, CM .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1999, 31 (01) :39-49
[10]   Does a change in angiotensin II formation caused by antihypertensive drugs affect the risk of stroke? A meta-analysis of trials according to treatment with potentially different effects on angiotensin II [J].
Boutitie, Florent ;
Oprisiu, Roxana ;
Achard, Jean Michel ;
Mazouz, Hakim ;
Wang, Jiguang ;
Messerli, Franz H. ;
Gueyffier, Francois ;
Fournier, Albert .
JOURNAL OF HYPERTENSION, 2007, 25 (08) :1543-1553